Table IV.

Effect of forbesione on IHC scores for the expression of CK19, PCNA, cyclin A, Bcl-2, Bax, caspase-9 and caspase-3 in allograft tissues.

		IHC score
Antigen	Groups	0 n (%)	1 n (%)	2 n (%)	3 n (%)	4 n (%)	P-value
CK19	Control	0 (0)	0 (0)	1 (25)	1 (25)	2 (50)
	Forbesione (50 mg/kg)	0 (0)	1 (25)	2 (50)	1 (25)	0 (0)	0.036a
PCNA	Control	0 (0)	0 (0)	1 (25)	3 (75)	0 (0)
	Forbesione (50 mg/kg)	0 (0)	2 (50)	2 (50)	0 (0)	0 (0)	0.032a
Cyclin A	Control	0 (0)	0 (0)	0 (0)	1 (25)	3 (75)
	Forbesione (50 mg/kg)	0 (0)	0 (0)	3 (75)	1 (25)	0 (0)	0.028a
Bcl-2	Control	0 (0)	0 (0)	2 (50)	0 (0)	2 (50)
	Forbesione (50 mg/kg)	0 (0)	1 (25)	3 (75)	0 (0)	0 (0)	0.039a
Bax	Control	0 (0)	1 (25)	2 (50)	0 (0)	1 (25)
	Forbesione (50 mg/kg)	0 (0)	0 (0)	0 (0)	2 (50)	2 (50)	0.039a
Caspase-9	Control	0 (0)	0 (0)	2 (50)	1 (25)	1 (25)
	Forbesione (50 mg/kg)	0 (0)	0 (0)	0 (0)	2 (50)	2 (50)	0.028a
Caspase-3	Control	0 (0)	1 (25)	2 (50)	0 (0)	1 (25)
	Forbesione (50 mg/kg)	0 (0)	0 (0)	1 (25)	0 (0)	3 (75)	0.039a

The CK19, PCNA, cyclin A, Bcl-2, Bax, caspase-9 and caspase-3 IHC results are represented as follows: 0, completely negative; 1, <25% of CCA area (faint positivity); 2, 25–50% of CCA area (moderate positivity); 3, >50–75% of CCA area (strong positivity); and 4, >75% of CCA area (extremely strong positivity).

^aSignificant difference between control and treatment group (P<0.05). IHC, immunohistochemical; CCA, cholangiocarcinoma; CK, cytokeratin; PCNA, proliferating cell nuclear antigen; Bcl, B-cell lymphoma; Bax, Bcl-2-like protein 4.